Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA [PDF]
Neuropsychiatric Disease and Treatment, 2023 Xu Chen,1,2,* Xuan Hou,3,* Daisy Bai,4 Rosanne Lane,5 Chong Zhang,6 Carla Canuso,7 Gang Wang,1,2 Dong-Jing Fu7 1The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital ...
Chen X +7 more
doaj +2 more sources
A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application [PDF]
PharmaceuticalsThis study assesses the early effectiveness of esketamine nasal spray (ESK) in adults with treatment-resistant depression (TRD) 1 day after the first administration, as monitored through self-assessment via the mobile application, Esketamine Continuing ...
Junhyung Kim +6 more
doaj +2 more sources
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Biomarkers in NeuropsychiatryTreatment-resistant depression, defined as a failure of at least two oral antidepressants of adequate dose and duration in the current episode, is a debilitating condition with low rates of response and remission.
Maxwell Z. Price, Richard L. Price
doaj +2 more sources
Weight changes in esketamine nasal spray and quetiapine extended-release treated patients with treatment resistant depression: Results from ESCAPE-TRD study [PDF]
European PsychiatryIntroduction In ESCAPE-TRD, esketamine nasal spray (ESK-NS) significantly increased the probability of remission at Week (Wk)8 and being relapse‑free through Wk32 after remission at Wk8 versus (vs) quetiapine extended-release (QTP-XR), in patients (pts)
A. Reif +7 more
doaj +2 more sources
Esketamine Nasal Spray versus Quetiapine for Resistant Depression
New England Journal of MedicineHorowitz, Mark A +2 more
openaire +6 more sources
Middle East Current Psychiatry, 2023 Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse.
Nahida Nayaz Ahmed +5 more
doaj +1 more source
Esketamine Nasal Spray for Treatment-Resistant Depression [PDF]
Nursing for Women's Health, 2020 Major depression affects millions of adults in the United States, and women are affected at twice the rate of men. Approximately 30% of individuals may continue to experience depression symptoms despite treatment with oral antidepressants. In March 2019, the U.S.
openaire +3 more sources
Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention—Mechanisms and Pharmacodynamics
Neuropsychiatric Disease and TreatmentHui Song,1,* Yang Luo,2,* Lingzhi Fang1 1The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, People’s Republic of China; 2Jiang You Third People Hospital, Mianyang, Sichuan, People’s Republic of China*These ...
Song H, Luo Y, Fang L
doaj +1 more source
Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs [PDF]
, 2020 Intranasal ketamine has recently gained interest in human medicine, not only for its sedative, anaesthetic or analgesic properties, but also in the management of treatment resistant depression, where it has been shown to be an effective, fast acting ...
Croubels, Siska +6 more
core +1 more source
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Annals of General Psychiatry, 2020 Background Patients with depression who are treated with esketamine nasal spray may commonly experience dysgeusia (bad/metallic/bitter taste) and related side effects such as nausea and vomiting.
Nicholas A. Bossaller +1 more
doaj +1 more source